Metabolic characteristics of study participants.

<p>Metabolic characteristics of study participants.</p

Correlation matrix between metabolic and anthropometric characteristics of study participants.

<p>Correlation matrix between metabolic and anthropometric characteristics of study participants.</p

Partial linear correlation coefficients of serum TRAIL levels and metabolic characteristics of study participants.

<p>Partial linear correlation coefficients of serum TRAIL levels and metabolic characteristics of study participants.</p

Multivariable linear regression models predicting serum TRAIL levels according to selected metabolic characteristics of study participants.

<p>Model 1 adjusted for age and gender.</p><p>Model 2 adjusted for age, gender and C-reactive protein.</p><p>Model 3 adjusted for age, gender, C-reactive protein and all variables included in table.</p><p>Model 4 Model 3 with stepwise backward selection of unnecessary variables (p for removal 0.1).</p

Characteristics of study participants according to TRAIL distribution.

<p>Characteristics of study participants according to TRAIL distribution.</p

Association between TRAIL and BNP adjusted for demographic and clinical parameters (multivariable linear regression analysis).

<p>BMI = body mass index; QWMI = Q-wave myocardial infarction; UA = unstable angina.</p

Subcloning potential of EPC/ECFC generated from the PBMC of ACS patients.

<p>After <i>ex-vivo</i> expansion, primary EPC/ECFC colonies were trypsinized and assessed for clonogenic potential capacity by single cells replating assay. In <b>A</b>, single cells derived from EPC/ECPF colonies were seeded in collagen I coated wells and monitored day by day (<b>a</b>: day 1; <b>b</b>: day 2; <b>c</b>: day 3; <b>e–f</b>: day 4; <b>a–e</b>: original magnification 25X; <b>f</b>: original magnification 40X). One representative experiment is shown. In <b>B</b>, secondary clones were classified on the basis of their proliferation properties. Data are mean±SD derived from six independent experiments.</p

Association between TRAIL and CK-MB adjusted for demographic and clinical parameters (multivariable linear regression analysis).

<p>BMI = body mass index; QWMI = Q-wave myocardial infarction; UA = unstable angina.</p

Serum TRAIL levels in AMI patients and healthy individuals.

<p>Levels of TRAIL were determined by ELISA in sera from AMI patients (analyzed at the indicated times post AMI) and from healthy control subjects. Horizontal bars are median, upper and lower edges of box are 75th and 25th percentiles, lines extending from box are 10th and 90th percentiles.</p

Serum TRAIL levels in AMI patient with respect to adverse clinical events.

<p>Serum levels of TRAIL were analyzed in AMI patient who died or experienced HF (with events) either during the acute phase (in-hospital) or in the follow-up (12 months after AMI) with respect to the other AMI patients (without events). Horizontal bars are median, upper and lower edges of box are 75th and 25th percentiles, lines extending from box are 10th and 90th percentiles.</p